IPM Take
ALS families know the cruelty of time. A 24-week trial period is not just a protocol window; it is months of function, speech, movement, breathing and planning. Coya’s blinded extension phase matters because longer exposure may help clarify whether its Treg-focused immunomodulatory approach has a meaningful signal. But the caution is essential: this is a trial milestone, not efficacy proof. ALS has seen enough hope collapse under weak evidence. The field needs speed, but it also needs trust.
Executive Summary
Coya Therapeutics announced that the first cohort of patients in the ALSTARS Phase 2 trial has entered the blinded active-treatment extension phase. Patients who completed the initial 24-week double-blind, placebo-controlled phase move into an additional 24-week blinded extension. In the extension, all participants receive COYA 302, with placebo patients re-randomized to one of two pre-specified dosing regimens. COYA 302 is an investigational biologic combination therapy intended to enhance regulatory T-cell function and reduce inflammatory activity relevant to ALS.
Why it matters
- Patients / caregivers: ALS trials are lived in real time. Longer participation must be meaningful, safe and respectful of disease progression.
- Researchers / clinicians: Extension data can help understand durability, safety and potential biological effect, but it cannot substitute for controlled efficacy results.
- Regulators / payers: ALS remains a pressure test for how evidence is generated when patients cannot wait and false hope is costly.
ALS is not patient with the trial system.
The disease moves while protocols are written, while visits are scheduled, while data are cleaned. Patients and families do not experience “study duration” as a technical term. They experience it as time.
Coya’s ALSTARS update therefore has weight. The first cohort entering the blinded active-treatment extension means the programme is moving into a longer evidence window. That matters for a therapy built around immune regulation, where durability and safety over time are central questions.
COYA 302 combines low-dose interleukin-2 and a CTLA-4 Ig component, aiming to enhance regulatory T-cell function and reduce inflammatory activity. The idea is biologically plausible, but still investigational.
The affected population is adults with ALS participating in the ALSTARS study across North America. The news should not be framed as a treatment win. It should be framed as an evidence-development milestone.
For IPM, the message is sharp. ALS needs better trials, not just more trial announcements. Extension phases can help, especially when they preserve blinding and gather longer safety and treatment data. But the bar must stay high because patients have already paid too much for promises that did not hold.
